Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02075008 · ClinicalTrials.gov registry record · Phase 2

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

A Phase 2 study, sponsored by Novartis Pharmaceuticals.

Terminated
Registry status
Phase 2
Development phase
270
Enrollment target

NCT02075008: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.

NCT02075008 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 270 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (103% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02075008, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.

TERMINATED
Registry status
Phase 2
Development phase
270 participants
Enrollment target

Study Summary

This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.

Primary Outcome

Safety was monitored throughout the study.

Interventions

  • DRUG QGE031

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2014-03-27
Est. Completion 2016-03-22
Phase Phase 2
Novartis Pharmaceuticals

1,375 total trials

Why NCT02075008 stopped before completion

NCT02075008 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (103% higher).

The record links to 0 conditions, and to 1 intervention - of which QGE031 is the first listed.

NCT02075008 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02075008 about?

NCT02075008 is a clinical study titled "Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201". This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.

What is the current status of trial NCT02075008?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2014-03-27. Estimated completion is 2016-03-22.

What interventions are being tested in trial NCT02075008?

The interventions under investigation include: QGE031 (DRUG).

Who is sponsoring clinical trial NCT02075008?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02075008's enrollment target sits among peer trials

270 205th of 2000 higher than 1,793 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02075008, the US trial registry maintained by the National Library of Medicine. NCT02075008 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.